TWO STEROIDAL ALKALOIDS FROM FRITILLARIA HARELINII

MIN ZHI-DA, QIAN JING-FANG, MUNEKAZU INUMA*, TOSHIYUKI TANAKA* and MIZUO MIZUNO*

Department of Phytochemistry, Nanjing College of Pharmacy, Nanjing, China; *Department of Pharmacognosy, Gifu Pharmaceutical University, 6-1 Mitahora-higashi 5 chome, Gifu 502, Japan

(Revised received 26 November 1985)

Key Word Index-Fritillaria harelinii; Liliaceae; steroidal alkaloids; peiminine; harepermine; hareperminside.

Abstract—Two new steroidal alkaloids named harepermine and hareperminside have been isolated from the bulbs of *Fritillaria harelinii* together with a known alkaloid, peiminine. The structure of the alkaloids were found to be 3β , 6β -dihydroxy- 5α , 14α , 17β -cevanine and its 3-O-glucoside on the basis of spectroscopic evidence.

INTRODUCTION

The bulbs of Fritillaria harelinii (Fish.) Regel ex Baker, which grows on sandbanks at Xinjiang in China [1], have been used as one of the traditional drugs for the treatment of coughs. This communication deals with new alkaloids to add to the interesting group of C-nor-D-homosteroidal alkaloids in Fritillaria species [2-5, 7].

RESULTS AND DISCUSSION

Compound 1, mp 213–214°, $[\alpha]_D$ –18.1° (c 2.0; CHCl₃), $C_{27}H_{43}NO_3$ was obtained as colourless crystals. The IR spectrum suggest that it contained hydroxyl groups (3450 cm⁻¹), a carbonyl group (1700 cm⁻¹) and a trans-quinolizidine moiety (2750 cm⁻¹). The mass spectrum showed fragments at m/z 429[M]⁺ and 112 (base peak). In the ¹H NMR spectrum, signals at δ 0.75 (3H, s), 1.03 (3H, s), 1.11 (3H, d, J = 6 Hz) and 3.56 (1H, m, $W_{1/2} = 24$ Hz) are assignable to the methyl protons at C-19, C-21, C-27 and a proton at C-3, respectively. Each methylene carbon in the ¹³C NMR spectrum is clearly assignable by the INEPT/R method (see Table 1). From the above spectral data, 1 was identified as peiminine [6]. The structure was further confirmed by comparison with an authentic sample.

Compound 2, mp 157-160°, $[\alpha]_D$ -18.7° (c 0.8; CHCl₃), C₂₇H₄₅NO₂ was obtained as colourless crystals. The presence of hydroxy groups and a trans-quinolizidine moiety were supported by the IR spectrum (3400 and 2780 cm $^{-1}$). The mass spectrum showed fragments at m/z415[M]+, 397[M-18]+, 344[M-71]+, 112, 111 (base peak) and 98. These spectral data indicate that 2 has a Cnor-D-homo-steroidal skeleton and that the hydroxyl group is not located at C-21. The ¹H NMR spectrum shows signals at 1.02 (Me-19), 3.67 ($W_{1/2} = 25$ Hz, H-3) and 3.86 (J = 8 Hz, H-6), respectively. These data are very similar to those obtained for isoverticine [7]. In the 13 C NMR spectrum, the carbons at δ 71.3 (C-3) and 72.5 (C-6) show a downfield shift in comparison with those found in isoverticine. Therefore, the two β -hydroxyl groups should be located at C-3 and C-6, respectively. The signal at C-19 (δ 1.02) in the ¹H NMR spectrum suggest that 2 possess trans-junctures between A/B, C/D, E/F and a cis-juncture between D/E [8]. In comparison with the

¹³C NMR spectrum of shinonomenine and isoverticine [9], the ¹³C-signals of C-16, C-17, C-18 and C-22 of 2 are shifted to highfield. The signals of delavine [10] isolated from F. delavayi are in agreement with those of 2. Therefore 2 has a cis-juncture between E/F and the H-17 of 2 has the β-configuration. The structure of 2 can therefore be assigned as 3β , 6β -dihydroxy- 5α , 14α , 17β -cevanine.

Compound 3, mp 168–170°, $[\alpha]_D - 27^\circ$ (c 0.5; MeOH), C₃₃H₅₅NO₇ was obtained as colourless crystals, which gave a positive Molish test. The IR spectrum showed hydroxyl absorption and a trans-quinolizidine moiety at 3425 and 2750 cm⁻¹. In the mass spectrum, fragments at 577 [M]⁺, 415 (aglycone) and 111 (base peak) were observed. The above spectral data show that 3 is a C-nor-D-homosteroidal alkaloid glycoside. The chemical shifts of the carbon in the ¹³C NMR spectrum are similar to 2 with the signal at C-3 (δ 78.7) shifted downfield by 7.4 ppm. The glycosylation shift shows that the sugar moiety is attached to C-3. The sugar moiety was determined as β -glucopyranose by ¹³C NMR (C-1', δ 102.3; $J_{^{1}H^{-12}C} = 142 \text{ Hz};$ measured INEPT/NON). by Consequently, 3 is the 3-O- β -D-glucopyranoside of 2, 6β hydroxy- 5α , 14α , 17β -cevanine- 3β -O-glucopyranoside.

2 R = H 3 R = β - D - glucoside Short Reports 2009

Table 1. ¹³CNMR spectral data of 1, 2 and 3 (pyridine-d₅)

Carbon			
no.	1	2	3
1	37.1	37.1	39.6
2	32.6	32.6	32.2
3	71.3	71.3	78.7
4	31.5	34.0	33.9
5	56.5	49.1	48.7
6	210.5	72.5	72.5
7	46.2	40.1	40.3
8	42.0	39.3	39.4
9	56.8	58.7	58.7
10	38.3	36.5	36.7
11	29.4	31.4	30.1
12	41.4	40.4	40.1
13	39.4	40.2	41.1
14	44.4	42.0	41.8
15	24.9	30.6	28.9
16	21.0	18.2	18.1
17	49.2	42.0	42.1
18	62.7	59.2	59.0
19	12.4	15.3	15.9
20	70.1	40.3	40.0
21	21.8	16.1	15.0
22	70.3	61.8	62.0
23	19.6	26.3	27.1
24	30.0	31.5	31.5
25	28.2	31.5	31.1
26	62.4	61.7	61.2
27	17.6	19.9	19.7
1'			102.3
2'			75.4
3'			78.2
4'			72.2
5'			78.€
6′			63.3

EXPERIMENTAL

Extraction and isolation. Dried bulbs (10 kg) were percolated with EtOH and the percolate coned to give a brown residue. The residue was dissolved in 3% HCl, the acidic soln filtered and adjusted to pH 10 with NH₄OH. The aq. soln was extracted with CHCl₃ and the extract chromatographed by rotary TLC on silica gel (satd with NH₃ gas for 5 min) with CHCl₃-MeOH (9:1) to give compounds 1 (30 mg) and 2 (40 mg). The EtOAc extract obtained was treated in the same manner as the CHCl₃ extract.

The solvent system used for rotary TLC was CHCl₃-MeOH-H₂O (13:7:2, lower phase). From the EtOAc extract, compound 3 was obtained (120 mg).

Compound 1 (peiminine). Colourless powder, mp 213–214°, $[\alpha]_{\rm D} - 18.1^{\circ}$ (c 0.2; EtOH); M, 429, $C_{27}H_{43}NO_3$. UV $\lambda_{\rm max}^{\rm EiOH}$ nm (loge): 287 (1.88). IR $\nu_{\rm max}^{\rm EiBF}$ cm $^{-1}$: 3450, 2950, 2750, 1705, 1463, 1054. 1 H NMR (CDCl₃, 90 MHz); δ 0.75 (3H, s, Me-19), 1.03 (3H, s, 21-Me), 1.11 (3H, d, J = 7 Hz, 27-Me), 3.56 (1H, m, $W_{1/2}$ = 24 Hz, H-3 α). MS (m/z): 429 [M] * , 414, 411, 386, 384, 372, 358, 238, 234, 217, 180, 164, 156, 155, 154, 140, 125, 112 (base), 111, 98. Compound 2 (harepermine). Colourless powder, mp 157–160° (EtOH), M, 415, $C_{27}H_{45}NO_2$, [α]_D -18.7° (c 0.8; CHCl₃). IR $\nu_{\rm max}^{\rm KBT}$ cm $^{-1}$: 3400, 2950, 2780, 1460, 1380, 1130, 1058, 1035, 1010. 1 H NMR (CDCl₃, 90 MHz); δ 0.81 (3H, d, d) = 6.2 Hz, 21-Me), 0.82 (3H, d, d) = 6 Hz, 27-Me), 1.02 (3H, s, 19-Me), 3.67 (1H, m, $W_{1/2}$ = 25 Hz, H-3 α), 3.86 (1H, br d, d) = 8 Hz, H-6 α). MS m/z

(100), 98 (33).

Compound 3 (hareperminside). Colourless powder, mp $168-170^{\circ}$, [α]_D -27° (c 0.5; MeOH), M, 577, $C_{33}H_{35}NO_7$. IR $\nu_{\text{max}}^{\text{KBr}}$ cm $^{-1}$: 3425, 2950, 2750, 1650, 1485, 1370, 1080, 1030, 750. 1 H NMR (C_6D_5N , 270 MHz): δ 0.80 (3H each, d, J = 5.0 Hz, 21-Me, 27-Me), 1.08 (3H, s, 19-Me). MS m/z (rel. int.): 577 [M] $^+$ (47) 576 (19), 562 (7), 559 (3), 520 (8), 415 (6), 218 (2), 178 (1), 164 (5), 150 (2), 139 (4), 125 (5), 124 (2), 112 (50), 111 (100), 98 (24).

(rel. int.); 415 [M] * (31), 414 (25), 297 (5), 358 (13), 344 (2), 214 (25), 178 (3), 164 (8), 150 (4), 139 (5), 125 (5), 124 (6), 112 (53), 111

Acknowledgement—The authors are grateful to Mr. Wu Ji-jhou (Hybei Institute for Drug Control, Wuhan, China) for a sample of peiminine.

REFERENCES

- Institute of Botany, Academia Sinica (1976) Iconographia Cormophytorum Sinicorum, Tomus V, pp. 459–460.
- Qing-Han Liu, Xiao-Guang Jia, Yong-Fang Ren Muhatal and Xeao-Tian Liaug (1984) Acta Pharm. Sin. 19, 894.
- Dong-Min Xu, Ben Ahang, Huan-Rong Li and Mao-Li Xu (1982) Acta Pharm. Sinica, 17, 555.
- Kaneko, K., Naruse, N., Tanaka, M., Yoshida, N. and Mitsuhashi, H., (1980) Chem. Pharm. Bull. 28, 3711.
- Kitajiam, J., Noda, N., Ida, Y., Miyahara, K., and Kawasaki, T. (1981) Heterocycles 15, 781.
- 6. Jin-Hou Wu (1982) Chinese Traditional and Herbal Drugs
- Kaneko, K., Naruse, N., Haruki, K. and Mitsuhashi, H. (1980) Chem. Pharm. Bull. 28, 1345.
- 8. Shakirov, R. and Yumsov, Y. (1980) Chem. Nat. Compds 6.
- Kaneko, K., Tanak, M., Haruki, K., Naruse, N. and Mistuhashi, H. (1979) Tetrahedron Letters 3757.
- Kaneko, K., Satsuhara, T., Ooka, T., Mitsuhashi, H., Hsu, H. and Chen, Y. (1985) Announcement at 105th Annual Meeting of The Pharmaceutical Society of Japan, Kanazawa.